5Furuy N, Kawas M, Hasebe O, et al. Comparative study of CA242 and CA19 - 9 in chronic panereatitis. Br J Cancer,1996,73:372.
6Kokhanenko NIU,Ignashov AM, Varga EV,et al. Role of the tumor markers CA19 -9 and carcino embryonic antigen(CEA) in diagnosis, treatment and prognosis of pancreatic cancer. Vopr Onkol, 2001, 47 (3) :294 -297.
9Aoki Y, Yanagisawa Y, Ohfusa H, et al. Elevation of serum CA19 - 9 in parallel with HbAlc in a diabetic female with the Lewis ( a + h - ) blood group. Diabetes Res Clin Pratt, 1991,13 ( 1 - 2) : 77-81.
3Fateh-moghadam A, Stieber P. Sensible use of tumour markers[M]. Roche Ltd, 1996,15-38.
4Klapdor R. Tumour markers in clinical oncology an overview[J]Sorin Biomedica,1994,33-45.
5Sakahara H, Endo K, Nakajima K et al. Serum CA-199 concentrations and computed tomography findings in patients with pancreatic carcinoma[J]. Cancer, 1996. 57,1324-1326.
6Campanelli G, Cavagnoli R, Cloffi U, et al. Can laparoscopic choloecystectomy be a day surgery procedure? Hepatogastroenterology,1988,45(23): 1422 - 1429.
7Feng D, Zhang S, Han T, et al. A prospective study of detection of panceratic carcinoma by combined plasma K-ras mutations with serum CA19-9 analysis. Pancereas, 2002, 25(4): 336 - 341.
8Sturm PD, Rauws EA, Hruban RH, et al. Clinical value of K-ras codon 12analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis. Clin Cancer Res, 1999, 5(3): 629 - 635.
9Kondo H, Sugano K, Fukaya N, et al. Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancere, 1994, 73 ( 1 ): 1589 - 1594.
10Lguchi H, Sugano K, Pukayama N, et al. Analysis of K-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer.Gastroenterology, 1996, 110 ( 1 ): 221 - 226.
